- Home
- DSGN vs TCPC Comparison
DSGN vs TCPC Comparison
Compare DSGN & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- TCPC
- Stock Information
- Founded
- DSGN 2017
- TCPC 2006
- Country
- DSGN United States
- TCPC United States
- Employees
- DSGN N/A
- TCPC N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- TCPC Finance/Investors Services
- Sector
- DSGN Health Care
- TCPC Finance
- Exchange
- DSGN Nasdaq
- TCPC Nasdaq
- Market Cap
- DSGN 418.1M
- TCPC 478.8M
- IPO Year
- DSGN 2021
- TCPC 2012
- Fundamental
- Price
- DSGN $8.78
- TCPC $5.73
- Analyst Decision
- DSGN Buy
- TCPC Sell
- Analyst Count
- DSGN 1
- TCPC 2
- Target Price
- DSGN $13.00
- TCPC $6.50
- AVG Volume (30 Days)
- DSGN 427.2K
- TCPC 640.0K
- Earning Date
- DSGN 11-05-2025
- TCPC 11-06-2025
- Dividend Yield
- DSGN N/A
- TCPC 21.31%
- EPS Growth
- DSGN N/A
- TCPC N/A
- EPS
- DSGN N/A
- TCPC N/A
- Revenue
- DSGN N/A
- TCPC $219,119,058.00
- Revenue This Year
- DSGN N/A
- TCPC N/A
- Revenue Next Year
- DSGN N/A
- TCPC N/A
- P/E Ratio
- DSGN N/A
- TCPC N/A
- Revenue Growth
- DSGN N/A
- TCPC N/A
- 52 Week Low
- DSGN $2.60
- TCPC $5.39
- 52 Week High
- DSGN $8.89
- TCPC $9.72
- Technical
- Relative Strength Index (RSI)
- DSGN 68.78
- TCPC 48.04
- Support Level
- DSGN $7.25
- TCPC $5.55
- Resistance Level
- DSGN $8.80
- TCPC $5.91
- Average True Range (ATR)
- DSGN 0.69
- TCPC 0.14
- MACD
- DSGN 0.12
- TCPC 0.02
- Stochastic Oscillator
- DSGN 93.42
- TCPC 43.83
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.